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Abstract
Mendelian randomization (MR) uses genetic information to strengthen
causal inference concerning the effect of exposures on outcomes. This
method has a broad range of applications, including investigating risk
factors and appraising potential targets for intervention. MR-Base has
become established as a freely accessible, online platform, which
combines a database of complete genome-wide association study results
with an interface for performing Mendelian randomization and sensitivity
analyses. This allows the user to explore millions of potentially causal
associations. MR-Base is available as a   or as an web application R
. The technical aspects of the tool have previously beenpackage
documented in the literature. The present article is complimentary to this as
it focuses on the applied aspects. Specifically, we describe how MR-Base
can be used in several ways, including to perform novel causal analyses,
replicate results and enable transparency, amongst others. We also
present three use cases, which demonstrate important applications of
Mendelian randomization and highlight the benefits of using MR-Base for
these types of analyses.
Keywords
Mendelian randomization, GWAS, causal inference, causality, sensitivity
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Introduction
Mendelian randomization (MR) is a method for strengthen-
ing the causal inference concerning the effects of risk factors 
and exposures on outcome traits using genetic variation1. 
Two-sample Mendelian randomization is an extension of this 
method that allows the use of summary statistics from genome- 
wide association studies (GWASs) in place of individual-level 
genetic data. Mendelian randomization can be used across 
multiple health outcomes for several applications, as detailed 
in Box 1. However, the data required to perform the analy-
sis and knowledge of the latest methods can be inaccessible. 
MR-Base2 combines a database of summary statistics on traits 
and health outcomes from over 20,000 GWASs, with an inter-
face for performing two-sample Mendelian randomization to 
simplify the implementation of this method. As of February 
2019, the repository was populated by curated and harmonized 
datasets corresponding to over 250 billion single nucleotide pol-
ymorphisms (SNP)-trait associations3. It is available via a web 
interface or through the package ‘TwoSampleMR’ for R. Useful 
links, including these, can be found in Box 2.
Box 1. Applications of MR-Base
Subject to suitable data and appropriate methods being 
available, Mendelian randomization can be implemented across 
multiple health outcomes to:
•    Identify novel (or confirm previously reported) risk and 
prognostic factors
•    Evaluate potential interventions for follow-up in 
independent replication or experimental studies, based 
on robust causal analysis and data-integration across 
multiple study designs, without exposure of patients
•    Predict unexpected effects (adverse and beneficial) of 
an intervention
•    Strengthen causal inference based on exploratory 
analyses from clinical trials
•    Investigate potential biological mechanisms 
underpinning risk factor-disease associations
Box 2. Useful links
•    MR-Base web application: http://www.mrbase.org/
•    Exemplar code for the use cases: https://github.com/
MRCIEU/mrbase_casestudies
•    MR-Base PheWAS web application: http://phewas.
mrbase.org/
•    TwoSampleMR R package: https://github.com/MRCIEU/
TwoSampleMR/
•    MRInstruments R package: https://github.com/MRCIEU/
MRInstruments/
•    TwoSampleMR R package wiki: https://mrcieu.github.
io/TwoSampleMR/
•    Mendelian randomization primer: https://youtu.be/
LoTgfGotaQ4
•    Mendelian randomization podcast: https://soundcloud.
com/bmjpodcasts/mendelian-randomisation-for-the-
moderately-intelligent
•    Mendelian randomization webinar: https://www.youtube.com/
watch?v=pc3uQz06gO8&feature=youtu.be&app=desktop
The rationale for the development of MR-Base was to pro-
vide easy access to analysis-ready data and allow system-
atic application of Mendelian randomization methods. The 
tool was developed in the R statistical environment and has an 
application programming interface that controls user interac-
tion with the underlying database, where curated GWAS data 
are stored and can be queried. Further technical details can be 
found in the existing MR-Base article3. The aim of this arti-
cle is to describe how the MR-Base platform can be used in 
practice (for example, for triangulation and transparency) 
and demonstrate these uses, through examples, to new audi-
ences. It is complimentary to the existing MR-Base article, 
which focuses on describing and demonstrating MR-Base as a 
resource.
Principles of Mendelian randomization
Mendelian randomization is a method to assess the causal effect 
of an exposure on an outcome using an instrument, defined by one 
or more SNPs, as a proxy for the exposure. The SNPs are used 
as instrumental variables and must meet three conditions: (i) they 
must be associated with the exposure; (ii) they must only affect 
the outcome via the exposure; and (iii) there must be no fac-
tor that causes both the SNP and outcome. These conditions are 
known as the instrumental variable assumptions and are illustrated 
in Figure 1. SNPs are plausible instruments because they 
are determined at conception and generally cannot be subse-
quently affected by the environment4. If these assumptions hold, 
then Mendelian randomization effect estimates are unlikely 
to be due to confounding or reverse causation. However, 
Mendelian randomization is still subject to important limitations. 
For example, effect sizes may not be indicative of the effects 
of a clinical intervention later in life. This can occur for 
several reasons, such as cumulative exposure, where Mendelian 
randomization estimates may reflect the effect of lifelong expo-
sure, or time-dependent exposure, where intervention outside of 
a critical period does not have an effect despite the Mendelian 
randomization estimates suggesting an effect exists. Mendelian 
randomization estimates may also be affected by issues 
such as horizontal pleiotropy, whereby the SNPs cho-
sen to proxy the exposure may affect the outcome by path-
ways other than the exposure of interest leading to biased 
results1,5–11.
Methodological advances mean that Mendelian randomiza-
tion can be implemented using summary statistics from GWAS, 
without individual level data12. In addition, the SNP-exposure 
associations and the SNP-outcome associations can be obtained 
from separate datasets, known as two-sample Mendelian 
randomization12. This is in contrast to one-sample Mende-
lian randomization, where both the exposure and outcome are 
measured in all individuals from the same sample. As a result, 
two-sample Mendelian randomization can exploit much larger 
sample sizes and estimate effects with higher precision than is 
typically possible using any single sample. It also allows access 
to large case control studies of disease outcomes that may not 
have measured the exposure of interest. This can be particularly 
beneficial when considering expensive or difficult to measure 
phenotypes, such as DNA methylation, metabolomics, proteomics, 
and gene expression8.
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Detailed discussion of the theory and interpretation of Mendelian 
randomization results, including the limitations of the method, 
can be found elsewhere1,5–10. Key definitions used throughout 
the present discussion are given in Table 1.
Potential applications of MR-Base
MR-Base2 is suitable for a broad range of applications and, 
consequently, is intended for use by a broad range of profes-
sionals. These include clinical and non-clinical researchers, 
public health specialists, policy makers and those in the pharma-
ceutical industry. Some of the key ways in which the platform 
can be used are summarised below and specific use cases are 
discussed in the Use cases section.
•    MR-Base can be used to rapidly implement two- 
sample Mendelian randomization to investigate potential 
risk and prognostic factors (use cases 1 and 2) and evalu-
ate potential drug targets (use case 3). The GWAS data-
base and online analytical platform provided by MR-Base 
allow two-sample Mendelian randomization to be imple-
mented quickly and easily to test associations for a range 
of traits (behavioural, physiological, hormonal, epig-
enomic, metabolomic, microbiomic) in relation to out-
comes. This can be used without the need to generate new 
data, for example, when exploring new research ideas. 
Note that these investigations are subject to the relevant 
data being made available and appropriate methods being 
developed. For instance, it is currently difficult to study 
prognostic factors due to the lack of GWAS conducted 
for disease progression outcomes and the susceptibil-
ity of current methods to collider bias13. However, new 
data are regularly added to the database and the platform 
is regularly updated to incorporate the latest methods, 
which should help to overcome these issues in the future.
•    MR-Base can conduct sensitivity analyses (use case 2). 
As with all analytical methods, Mendelian randomiza-
tion methods are based on assumptions which may not 
hold. MR-Base offers many Mendelian randomization 
methods for investigators to choose from and conducts 
several standard sensitivity analyses that allow relax-
ation of the assumptions and provide ways of assessing 
potential pleiotropy. Some of the more commonly used 
Mendelian randomization methods are selected by default 
in the platform, including the Wald ratio14, MR-Egger15 and 
the inverse variance weighted method15. Use of multiple 
methods is recommended as they differ in their strengths, 
limitations and efficiency. For example, MR-Egger has 
been developed to detect assumption violations such 
as invalid instruments due to pleiotropy but can lack 
precision. The best way to assess the reliability of the 
causal estimates obtained from Mendelian randomization 
is to triangulate across multiple Mendelian randomization 
methods and with findings from non-Mendelian ran-
domization study designs16. This is demonstrated 
in use case 2. Summary tables for the methods 
and the output of Mendelian randomization analy-
ses conducted using MR-Base (as of October 2018) are 
provided in Table 2 and Table 3, respectively. The 
platform continues to be under active development and, 
as highlighted before, new methods are added as they 
arise.
Figure 1. Overview of the instrument assumptions.
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Table 1. Key definitions.
Term Definition
Mendelian randomization Mendelian randomization is a method to assess the causal effect of an exposure on an outcome using an instrument, defined by one or more single nucleotide polymorphisms, as a proxy for exposure.
Genome-wide association 
study (GWAS)
Genome-wide association studies identify the genetic variants that are associated with a given 
phenotype.
Single nucleotide 
polymorphism A single nucleotide polymorphism is a difference in the DNA nucleotides between individuals. 
Triangulation
“The practice of obtaining more reliable answers to research questions through integrating results from 
several different approaches, where each approach has different key sources of potential bias that are 
unrelated to each other.”16
Pleiotropy Pleiotropy is when genetic variants effect multiple phenotypes that appear to be unrelated.
Horizontal pleiotropy
Horizontal pleiotropy occurs when the outcome is affected by the instrument single nucleotide 
polymorphism(s) through a pathway that is independent of the exposure and invalidates the second 
Mendelian randomization assumption. This is opposed to vertical pleiotropy, which occurs when 
the instrument single nucleotide polymorphism(s) are associated with other phenotypes that occur 
between exposure and outcome or after the outcome of interest and does not invalidate the Mendelian 
randomization assumptions.
Genome-wide significance A conventional threshold, defined as p-values less than 5e-8, that is commonly used to determine which genetic variants are ‘hits’ in a genome-wide association study.
Allele harmonization Allele harmonization is the process of specifying the effect and other alleles in the same way in both the outcome and exposure data. 
Clumping Clumping is a method for identifying the independent signals among correlated SNPs.
Linkage disequilibrium Two genetic variants are in linkage disequilibrium if their alleles are associated.
Heterogeneity Heterogeneity is defined as the variation in the causal estimate across SNPs.
Palindromic single 
nucleotide polymorphism 
(SNP)
A SNP is described as palindromic if the pair of alleles on the forward-strand are the same as the pair of 
alleles on the reverse strand (i.e. G/C or A/T SNPs).
Minor allele frequency (MAF) The MAF is a measure of how common the least common allele is for a given genetic variant.
Funnel plot Funnel plots present the effect estimates against a measure of precision – in the case of MR-Base, the inverse standard error of the instrument – to allow visual assessment of heterogeneity.
No measurement error 
(NOME) assumption
The NOME assumption assumes that the variance of the instrument-exposure association is negligible 
and so can be ignored.
Quantitative trait locus (QTL) A QTL is a DNA variant associated with the variation that is observed in a phenotype.
Zero modal pleiotropy 
assumption (ZEMPA) An assumption that the mode of the bias terms for individual instruments is zero.
•    MR-Base can replicate results (use cases 2 and 3). MR-
Base can be used to replicate the results of studies, 
regardless of whether they originally used Mendelian 
randomization or MR-Base, if relevant GWAS are avail-
able. This may be useful in several situations, including 
when appraising studies in the literature.
•    MR-Base can be used to support triangulation of evi-
dence (use case 2). Triangulation has been defined as “the 
practice of obtaining more reliable answers to research 
questions through integrating results from several differ-
ent approaches, where each approach has different key 
sources of potential bias that are unrelated to each other.”16 
Mendelian randomization, implemented in MR-Base, 
can be linked with other designs which are intended to 
reveal biases (for example, a negative control study) 
or exploit different confounder structures (for example, 
a cross-context comparison as a source of evidence in a 
triangulation framework).
•    MR-Base can enable transparency (use case 1). MR-Base 
has been developed to encourage transparency by pro-
viding the analysis code needed to replicate the analysis 
in the output. Further to this, studies that use data from 
the platform can be directly replicated by others as they 
can access the same data that has been formatted in a 
consistent manner via the provided allele harmonization 
procedures.
Methods
Implementation
MR-Base2 can perform two-sample Mendelian randomization 
and provide summary statistics from a range of GWAS for this 
purpose. As highlighted previously, it can be accessed through a 
web application or as an R package. Data can either be accessed 
through the platform or be uploaded by the user, both of which 
are demonstrated in the following Use cases section. Data 
harmonization between the SNP-exposure associations and the 
SNP-outcome associations and Mendelian randomization are 
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Table 2. Overview of MR methods available in MR-Base.
Method Details References
Wald ratio
The Wald ratio method is also known as the ratio of coefficients method. It divides the 
regression coefficient of the instrument on the outcome by the regression coefficient 
of the instrument on the exposure and can be used when only one instrument SNP is 
available. 
14
Maximum likelihood
This method maximizes the likelihood of a model, which is based on the exposure-
outcome relationship and the distribution of the estimates of the genetic association, to 
obtain a causal estimate.
17
MR Egger regression MR Egger calculates Wald ratios for each of the instruments and combines the results 
using an adapted Egger regression. The causal effect is the Egger regression slope 
coefficient and the intercept is an estimate of the average pleiotropic effect across 
instruments. Bootstrapping can help to improve the reliability of standard error estimates 
for non-zero causal effects.
15
MR Egger (bootstrap)
Simple median
These methods calculate Wald ratios for each of the instruments and select the median 
value (according to the specified method) as the causal estimate. They provide valid 
estimates when more than half of the SNPs satisfy the instrumental variable assumptions.
18,19Weighted median
Penalised weighted median
Inverse variance weighted This method calculates the Wald ratio for each of the instruments and combines the 
results using an inverse-variance weighted meta-analysis approach. The slope from 
this approach can be interpreted at the causal effect of the exposure on the outcome. 
The variance of the effect can be estimated using either a fixed or multiplicative random 
effects model. The latter is usually implemented unless there is under-dispersion in the 
effect estimates, in which case a fixed effects model is used. 
17,20
Inverse variance weighted 
(multiplicative random effects)
Inverse variance weighted 
(fixed effects)
Simple mode The mode-based methods use the causal effect estimates for individual SNPs to form 
clusters. The causal effect estimate is then taken as the causal effect estimate from the 
largest cluster of SNPs. The weighted mode methods use the same process but assign 
weights to each SNP. Mode-based methods require ZEMPA, which states that the mode 
of the bias terms for the individual instruments is zero. 
21
Weighted mode
Weighted mode (NOME)
Simple mode (NOME)
Table 3. Overview of the tables and graphs included in the MR-Base platform.
Tab Details
MR results A table with the causal estimates resulting from each MR method that was implemented. The effects are 
presented in the units of the exposure SNP(s).
Heterogeneity 
statistics
A table with statistics indicating the variation in the causal estimate across SNPs, i.e. heterogeneity. Lower 
heterogeneity indicates better reliability of results.
Causal direction test The results of a test that uses variation explained in both the exposure and outcome to assess whether the 
direction of the results is likely to be correct. Note the test cannot determine whether a causal association 
exists.
Horizontal pleiotropy The Egger regression intercept with its standard error and a p-value.
Single SNP analysis A summary graph showing the individual effects of SNPs, calculated using the Wald ratio, along with the overall 
results to assess the consistency across SNPs.
Method comparison 
plot
A graphical representation of the results given under the ‘MR results’ tab. This graph shows the effect of 
the SNP(s) on exposure against the effect of the SNP(s) on the outcome. The graph is structured so that the 
effect of the SNP(s) on the exposure is always positive and the effect of the SNP(s) on the outcome is directed 
accordingly.
Leave-one-out 
analysis
A graph showing the results of MR analyses using the inverse variance weighted method when leaving one SNP 
out each time. This analysis can be used to assess whether the SNPs are consistent in terms of their effect on 
the overall outcome or whether the results are being driven by a single outlying SNP.
Funnel plot A graph to visually assess heterogeneity, particularly horizontal pleiotropy. Horizontal pleiotropy is likely if points 
are spread. Directional horizontal pleiotropy may be present if the graph is not symmetrical. 
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then performed according to options specified by the user using 
buttons on the web application or commands for the R package.
Operation
The web application can be accessed from any platform that 
allows the use of a java-script compatible graphical web browser. 
The R package can be accessed from any platform where R 
version 3.5 or later can be installed. Step-by-step instructions 
for the web application and code for the R package are avail-
able for each of the use cases (see Software availability)22. 
A generalized workflow for using the MR-Base web interface 
is provided in Box 3.
Box 3. Generalized workflow for using the MR-Base web 
interface
Mendelian randomization analyses can be performed using the 
MR-Base web interface as detailed below:
1.    Access the platform (http://www.mrbase.org/) and sign 
the data access agreement using a Google account.
2.    Define the exposure according to one of the following 
options:
a.    By selecting the relevant GWAS from an existing 
source, such as the MR-Base GWAS catalog. This 
is demonstrated in use cases 1 and 2.
b.    By uploading an instrument file, specifying the 
delimiter for the file and filling in the form to map 
the column names to those supplied in the file. 
Columns not included in the file can be left blank in 
the mapping. This is demonstrated in use case 3.
3.    Define the outcome by selecting the relevant GWAS 
from the MR-Base GWAS catalog.
4.   Specify the analysis settings:
•    Set linkage disequilibrium (LD) clumping preference 
– by default this will be ‘Do not check for LD 
between SNPs’.
•    Set linkage disequilibrium proxies preference – by 
default this will be to use proxies with a minimum 
linkage disequilibrium R squared value of 0.8 
and allow palindromic SNPS with a minor allele 
frequency threshold up to 0.3.
•    Set allele harmonisation preference – by default 
this will be ‘Attempt to align strands for palindromic 
SNPs’. If used, this setting will remove palindromic 
SNPs with minor allele frequencies close to 0.5 as 
the effect allele will be ambiguous.
•    Select the methods for analysis – by default this 
will be the Wald ratio, MR Egger, weighted median, 
inverse variance weighted and weighted mode 
methods.
5.    Select the ‘perform MR analysis’ button and save the 
results, including the citations that are to be referenced 
in any published work arising from this analysis, on the 
following screen.
Note that the MR-Base web interface will provide the analysis 
code as an output if you wish to recreate your analysis in R. Also, 
note that there will be no graphical results produced for single 
SNP instruments as the sensitivity analyses, which are illustrated in 
the graphs, can only be conducted when there are multiple SNPs.
Use cases
We discuss three studies that demonstrate important applica-
tions of Mendelian randomization and highlight the benefits 
of using MR-Base for these types of analyses in the following 
sections.
Use case 1: subjective wellbeing and cardiometabolic 
health
Our first use case demonstrates the rapid implementation of 
Mendelian randomization using MR-Base to investigate a risk 
factor proposed in the observational literature and enable trans-
parency of the Mendelian randomization study. The specific 
workflow for this case study is provided, alongside the necessary 
code, data and results, on GitHub (see Software availability)22. 
It is based on work by Wootton et al. that used MR-Base to 
investigate the association between subjective wellbeing and 11 
measures of cardiometabolic health23. It has been reproduced 
based on information in the paper and, in particular, their code on 
GitHub. Studies with data on both subjective wellbeing and meas-
ures of cardiometabolic health are rare. Therefore, the authors 
chose to use two-sample Mendelian randomization so that they 
could use separate samples for their exposure (sample 1) and 
outcome (sample 2) phenotypes and use UK Biobank as a 
single-sample Mendelian randomization sensitivity analysis. In 
addition to this, the largest available GWAS of subjective well-
being at the time of the study had identified just three SNPs to 
instrument this phenotype at the conventional genome-wide 
significance level and only one of these three SNPs replicated 
in an independent sample. Consequently, the authors used a 
lower p-value threshold of P < 5×10-5 to increase the number of 
SNPs in their instrument. This potentially increases their instru-
ment strength but may also increase their susceptibility to 
weak instrument bias or pleiotropy.
It was straightforward to use two-sample Mendelian randomi-
zation with MR-Base in this study as it allowed the authors to 
consider multiple outcomes simultaneously and to use sum-
mary data that was already formatted for analysis. It also allowed 
specification of their preferred p-value threshold for the instru-
ment. To make allowance for the non-independence of the 
selected SNPs, it was necessary to prune the SNPs to deter-
mine an independent set for the analysis. MR-Base allows users 
to select independent SNPs through a process known as ‘clump-
ing’, which identifies independent signals by considering the 
linkage disequilibrium between SNPs. Linkage disequilibrium 
refers to the allelic association between groups of SNPs, 
which are typically located in a similar region of the genome. 
Failure to consider the linkage disequilibrium between SNPs 
can lead to overestimation of instrument strength and overly 
precise effect estimates. MR-Base overcomes this by picking 
the SNP from the group of SNPs in linkage disequilibrium that 
has the strongest evidence of association with the expo-
sure for use in the Mendelian randomization analysis. In 
the Wootton et al. study, clumping reduces the subjective 
wellbeing instrument from 724 SNPs to 84 SNPs, highlighting the 
importance of this step in the analysis. 
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Use case 2: systolic blood pressure and coronary heart 
disease
The second use case demonstrates how MR-Base can be used 
to conduct sensitivity analyses and triangulate evidence. The 
specific workflow for this case study is provided, alongside 
the necessary code, data and results, on GitHub (see Software 
availability)22. Sample code for using the ‘TwoSampleMR’ 
R package based on this use case is provided in Box 4. It is 
based on work by Ference et al. that examined the effect of systo-
lic blood pressure on coronary heart disease24. Here, we recreate 
the Mendelian randomization component of the work. This can 
be triangulated with evidence from meta-analyses of prospec-
tive observational studies and randomized controlled trials. These 
meta-analyses found that lower systolic blood pressure reduced 
risk of coronary heart disease with odds ratios of 0.75 (95% 
CI: 0.71 to 0.78; p = 0.006) and 0.83 (95% CI: 0.76 to 0.90; 
p = 0.001), respectively. A full discussion of the triangulation 
element of this research is provided by Lawlor et al.16
In our results, as with the original paper, we were concerned 
about directional pleiotropy, which occurs when genetic variants 
affect the outcome independently of the exposure. This is 
because large GWAS, such as the GWAS of systolic blood pres-
sure we use here, may identify SNPs of unknown function25. To 
assess the effect of this upon our results, we can look at the MR-
Egger regression intercept provided by default on the MR-Base 
web application and calculable using the TwoSampleMR pack-
age for R. The intercept provides an estimate of the magnitude 
of horizontal pleiotropy and in our case is -0.0087 (SE: 0.0059; 
p = 0.147). This suggests limited evidence for directional pleiot-
ropy among our results. We also used several Mendelian randomi-
zation methods for our analysis as a further sensitivity analysis 
and found consistent results for the effect of increased systolic 
blood pressure on coronary heart disease, regardless of the method 
used (IVW - OR: 1.76, 95% CI: 1.48 to 2.10, p = 3.92e-10; MR 
Egger - OR: 2.64, 95% CI: 1.49 to 4.68, p = 1.09e-03; Weighted 
median – OR: 1.77, 95% CI: 1.52 to 2.05, p = 3.92e-10; Weighted 
mode – OR: 1.77, 95% CI: 1.26 to 2.49, p = 1.31e-3).
Use case 3: HMGCR and type 2 diabetes
Our final use case demonstrates how MR-Base can be used to 
replicate a study and appraise a potential pharmaceutical inter-
vention. The specific workflow for this case study is provided, 
alongside the necessary code, data and results, on GitHub (see 
Software availability)22. It is based on research by Swerdlow 
et al. that investigated the effect of 3-hydroxy-3-methylglutaryl-
CoA reductase (HMGCR), the target of statins, on risk of type 2 
diabetes26. This study used a single SNP as an instrument: 
rs17238484. To demonstrate the features of MR-Base, we have 
uploaded the data necessary to define the instrument for this 
analysis, instead of using data already within the platform. 
These data were extracted from the 2013 GWAS by the Global 
Lipids Genetics Consortium27. Once uploaded, the column 
names must be mapped to those used by MR-Base before the 
analysis can be run. If you are using the R package, there are 
equivalent commands that perform data formatting (see this 
guide). Although units are not required for the analysis to run, 
it is important that the units of the instrument-exposure and 
instrument-outcome effects are known, as this determines the 
interpretation of the effect estimate obtained by Mendelian 
randomization. 
If you use MR-Base, please cite the resource using reference3. 
We also ask that you cite and acknowledge the studies that 
contributed the data and methodology used in your analysis.
Conclusions
Mendelian randomization is a method for estimating causal 
effects of an exposure on an outcome that are unlikely to be due 
to confounding or reverse causation. The method has a broad 
Box 4. Sample code for using the ‘TwoSampleMR’ R package based on use case 2
# Load the TwoSampleMR package
library(TwoSampleMR)
# List the outcomes available in MR-Base
ao <- available_outcomes()
# Extract the instruments from the systolic blood pressure GWAS (ID: 'UKB-a:360')
exposure_dat <- extract_instruments(c('UKB-a:360'))
# Extract the outcome data from the coronary heart disease GWAS (ID: 7)
outcome_dat <- extract_outcome_data(exposure_dat$SNP, c('7'),
                                    proxies = 1, rsq = 0.8, align_alleles = 1,
                                    palindromes = 1, maf_threshold = 0.3)
# Harmonize the exposure and outcome data
dat <- harmonise_data(exposure_dat, outcome_dat, action = 2)
# Perform MR analysis
mr_results <- mr(dat)
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range of applications, including the investigation of risk factors 
and the appraisal of potential targets for pharmaceutical 
intervention. MR-Base eases the implementation of this method 
by combining a database of GWAS results with an analysis inter-
face to allow Mendelian randomization to be used in several 
ways, such as for transparency and replication. Consequently, 
novice users can now perform sophisticated, causal appraisals of 
exposures by implementing Mendelian randomization using this 
powerful but accessible tool.
Data availability
Underlying data
Source data for the use cases are available through the data-
base integrated into the MR-Base platform. The database is 
large and contains data from over 20,000 GWAS; therefore, it is 
not possible to host this data on an external repository. The data 
can be accessed via the MR-Base web application or by using 
the TwoSampleMR package for R to interact with the applica-
tion programming interface. Users are required to accept the 
data access agreement by logging in with a Google account 
before access to the data is granted.
Software availability
MR-Base software:
-    Software available from: http://www.mrbase.org/
-    Source code available from: https://github.com/MRCIEU/
TwoSampleMR
-    Archived source code at time of publication: https://doi.
org/10.5281/zenodo.32980012
-    License: GPL-3.0
Use cases workflow and code:
-    Source code available from: https://github.com/MRCIEU/
mrbase_casestudies
-    Archived source code at time of publication: http://doi.
org/10.5281/zenodo.323931622
-    License: MIT
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This is an excellent instructional resource concerning use of Mendelian randomization (MR) and
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interpretation of MR-Base estimates in relation to causal inference, consolidated important limitations of
MR-Base into one comprehensive section and reflected more on the interpretation of the MR estimate.
Some of this information on limitations and interpretation of MR is already in the paper, but could be
consolidated and made more comprehensive for the intended target audience, while the first item should
be made clearer. Specifically,
The paper should make a clearer distinction between MR and causal inference. The
paper explains that MR addresses confounding and reverse causation. However, valid causal
inference requires estimates free from confounding and free from selection bias. So, the paper
should draw the reader’s attention to this difference. As such, it would be better to explain
throughout that MR gives unconfounded estimates rather than to equate MR with strengthening
causal inference. As a general “health warning” it should also be pointed out that all MR studies
depend on the assumption that the underlying genome wide association studies give unbiased
genetic estimates. That is not to detract from the strengths of MR-Base and MR but just to be clear
for the reader.
 
The sections explaining the limitations of MR and MR-Base would be better consolidated under a
heading “Limitations” for easy reference. The material in the second half of the paragraph on page
3 headed “Principles of Mendelian randomization” could be moved to this section. The sentences
at the bottom of page 4 explaining that MR cannot be used to assess disease progression could be
moved to this section. It might also be worth mentioning that MR may not give reliable estimates of
the effects of risk factors in samples of patients. 
 
More information on the interpretation of the MR estimate would also be helpful. Many MR
estimates rely on the INSIDE (instrument strength independent of the direct effect) assumption
which seems to imply that the MR estimate means that the exposure of interest or a precursor
sharing genetic predictors with the exposure could be causal.
MR-Base is a wonderful tool that generally gives the same results as MR conducted by hand or using
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MR-Base is a wonderful tool that generally gives the same results as MR conducted by hand or using
other packages. In that context, there are a few clarifications that would be helpful.
MR-Base users may not realize that the results are given in beta coefficients for the outcome which
needs to be exponentiated if the outcome is reported as logodds. Maybe this point could be added
to Table 3.
 
MR-Base has sometimes given different p-values for MR-Egger than the MendelianRandomization
package, possibly because MR-Base is using a t-distribution and MendelianRandomization is
using a normal distribution to obtain these p-values. Maybe this this difference is no longer relevant
but if it is still occurring it might be worth addressing it in some way.
 
The clump_data function of MR-Base could make it clear whether genetic variants are excluded
because they are correlated with the ones retained or because they are not in the 1000 genomes
catalog.
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The article by Walker   on using the MR-Base platform to investigate risk factors and drug targets foret al.
thousands of phenotypes is a welcome addition to the literature. Naturally, the authors wax lyrical about
the MR-Base platform they created and developed. It is indeed an attractive platform in that it holds
summary statistics on traits and health outcomes from over 20,000 GWAS. To search for relevant GWAS
and retrieve the data from scratch would have taken a researcher weeks and months, whereas with this
integrated platform, you can do this in a day once you have learnt how to use it. Another major advantage
of this platform is that it is transparent and enables other researchers to confirm the results using the
same database and the published analysis codes.
 
The article is concise and focuses on the information the end-user would want. Notably, three case
studies, or ‘use cases’, are discussed to illustrate the utility and advantages of MR-Base. The explanation
of two-sample Mendelian randomization tends to be brief, but this is reasonable, as the authors have
previously published extensively on the methodology.
 
All in all, MR-Base is an exciting innovation that has already produced some important findings and the
present article provides much practical information to enable interested researchers to explore and exploit
this new research tool.
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As ‘thousands of phenotypes’ is in the title, there should be some information on the quantity,
breadth and depth of the phenotypic variables. Part of the information can be given as a table if
appropriate.
In lieu of Discussion, there is a paragraph of conclusions. Regardless of what the section is called,
it would be nice if there were some discussions on the limitations of MR-Base.
Would this database continue to be free or would it require subscription or payment in the future?
In the Abstract, complementary was misspelt as complimentary.
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